IND filings rise
Commercial INDs received by CDER in 2005 reached 637, a 20-year high. A significant jump in commercial INDs started in 2004, with 621 received, suggesting that the transfer of therapeutic biologics from CBER to CDER could have contributed significantly. However, non-commercial INDs, which totaled 1,297 in 2005, are well within the broad range of the last 20 years...
You may also be interested in...
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by
California proposes limiting short-form Prop 65 warnings to products with 5 inches or less of labeling space, while prohibiting their use in online and catalog warnings. The number of products with the warnings, used even on vacuum cleaners, luggage and guitars, has made tracking them impossible.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.